Brief: Pharnext Announces Positive Topline Results From Pivotal Phase 3 Trial Of PXT3003
16/10/2018 06:41
Oct 16 (Reuters) - PHARNEXT SA PHARN.PA :
* PHARNEXT ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 TRIAL OF PXT3003 FOR
TREATMENT
OF CHARCOT-MARIE-TOOTH TYPE 1A DISEASE
* SAFE AND WELL TOLERATED, NO TREATMENT RELATED SERIOUS ADVERSE EVENT REPORTED IN HIGHER
DOSE
GROUP
* HIGHER DOSE MET PRIMARY ENDPOINT, OVERALL NEUROPATHY LIMITATION SCALE (ONLS), WITH
STATISTICAL
SIGNIFICANCE (P = 0.008)
* INTENDS TO FILE FOR MARKET APPROVAL IN US AND EUROPE
* ALSO EXPECTS TO INITIATE A PHASE 3 TRIAL OF PXT3003 IN PEDIATRIC CMT1A PATIENTS IN FIRST
HALF OF
2019
Source text for Eikon: ID:nEQ6tzqH7a
Further company coverage: PHARN.PA
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pharnext SCA
See all newsBrief: Pharnext Progresses On Charcot-Marie-Tooth Disease Study
Brief: Pharnext Reports Topline Results From Pivotal Phase III Clinical Trial Of PXT3003 In Charcot-Marie-Tooth Disease Type 1A
Brief: Pharnext Receives Offer Valuing Its Drug Candidate For Charcotmarie-Tooth Disease At Over Eur 500 Mln
Brief: Pharnext Appoints Dr Gilbert Wagener As Chief Medical Officer
Brief: Pharnext Reports Significant Progress In Search For Pharmaceutical Partners To Finance Its Development